CD22 Redirected Autologous T Cells for Acute Lymphoblastic Leukemia (ALL)
Contact
Description
The purpose of this study is to test an experimental approach called cell therapy for Leukemia that involves B cells (tumor cells). This is a study for people who have been previously treated for Leukemia. This study will take the participant's white blood cells (T cells) and then modify them in a lab to recognize and target the cancer cells. These modified cells are then put back into the body through infusion. If you have previously received a similar cell therapy, you may still be eligible for this study.
Eligibility and criteria
What to expect
Participation in this study will last up to 15 years, which includes long-term follow up. Participants will be followed closely for the first month after receiving CART22 cells, and then monthly for 6 months, every 3 months for up to 12 months, and every 6 months for up to 5 years, and annually for up to more 10 years.
This will involve the following tests and procedures:
- Receive lymphodepleting chemotherapy prior to infusion
- Receive CART22 infusion
- Have frequent clinic visits and monitoring the first month after infusion
- Have research blood samples drawn
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.